Corneal epithelium regeneration

Corneal epithelium regeneration is not a specific molecule, receptor, or canonical therapeutic target. Instead, it refers to the **biological process** by which the corneal epithelial layer repairs and renews itself following injury or normal turnover. This process involves several phases—latent/lag phase, migration, proliferation, and reattachment—coordinated by cellular remodeling, apoptosis of damaged cells, migration of healthy cells from the wound edge (often originating from limbal stem cells), and restoration of normal epithelial structure[1][2][3]. Key molecular players in this process include growth factors such as epidermal growth factor receptor (EGFR) family members and keratinocyte growth factor (FGF7/KGF), as well as signaling pathways like Wnt and Notch[4][5]. The regenerative capacity is crucial for maintaining corneal transparency and vision; failure leads to diseases such as limbal stem cell deficiency[5][7]. While many drugs or therapies aim to enhance this regenerative process—such as autologous limbal stem cell transplantation—the term itself does not denote a single druggable entity but rather a complex physiological phenomenon involving multiple molecular targets[4][5][7]. Because "corneal epithelium regeneration" is a **process**, not a discrete molecule or receptor, it should not be classified as a canonical therapeutic target. If you are seeking information on specific molecules involved in this process (e.g., EGFR1/ErbB1/Epidermal growth factor receptor 1), those would be appropriate entries for structured data on drug targets[4].